Dianthus Therapeutics announced an early GO decision in Phase 3 CAPTIVATE trial of claseprubart in CIDP after achieving 20 confirmed responders with less than 40 participants in Part A, and reported FY 2025 financial results including $514.4 million cash runway into 2028 and net loss of $162.3 million.
Key takeaways
Early GO decision in CAPTIVATE Part A with 20 confirmed responders from <40 participants, confirmed by DSMB with no related serious AEs
Phase 3 gMG trial of claseprubart 300mg/2mL Q2W/Q4W to initiate mid-2026, top-line 2H'28
Phase 2 MoMeNtum MMN trial top-line on track 2H'26
Phase 1 DNTH212 healthy volunteer data expected 2H'26
FY2025 net loss $162.3M or $4.20/share vs $85.0M or $2.55/share in 2024
Cash $514.4M as of Dec 31, 2025 provides runway into 2028